AFP and Cirrhosis: Age, sex, baseline HCV RNA load, HCV genotypes, clinical cirrhosis (TW0), AST (TW0), AFP (TW0), AFP decline (from the SVR visit to Y3 post-SVR), estimated glomerular filtration rate (TW0), platelets (TW0), international normalized ratio (INR) (TW0), LS (TW0), LS (SVR), median post-SVR follow-up months, and median post-Y3PSVR follow-up months differed significantly between the group that underwent IFN-based therapy (n = 406) and the group that underwent DAA-based therapy (n = 114, Table 1).